Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

IGC Pharma, Inc. Common Stock (NY:IGC)

0.2789 +0.0129 (+4.85%)

Official Closing Price Updated: 4:10 PM EST, Feb 24, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	567,034
Open	0.2713
Bid (Size)	0.2740 (8,000)
Ask (Size)	0.2749 (200)
Prev. Close	0.2660
Today's Range	0.2700 - 0.2856
52wk Range	0.2420 - 0.4985
Shares Outstanding	49,784,017
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets

Today 8:30 EST

Via ACCESS Newswire

IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial

February 23, 2026

Via ACCESS Newswire

Performance

YTD	-4.2%	-4.2%
1 Month	-4.0%	-4.0%
3 Month	-12.6%	-12.6%
6 Month	-25.3%	-25.3%
1 Year	-2.0%	-2.0%

More News

IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

February 17, 2026

Via ACCESS Newswire

IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets

February 12, 2026

Via ACCESS Newswire

IGC Pharma Announces Equity Research Update by Alliance Global Partners

February 10, 2026

Via ACCESS Newswire

IGC Pharma Expands Phase 2 CALMA Trial into Colombia's Premier Alzheimer's Research Center

February 09, 2026

Via ACCESS Newswire

IGC Pharma Reaches 70% Enrollment in Phase 2 CALMA Trial Evaluating IGC-AD1 for Alzheimer's Agitation

February 02, 2026

Via ACCESS Newswire

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York

January 22, 2026

Via ACCESS Newswire

IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Site at Dominion Medical Associates, a Lightship Network Site, in Richmond, Virginia

January 12, 2026

Via ACCESS Newswire

IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability

January 06, 2026

Via ACCESS Newswire

IGC Pharma Raises Capital to Advance IGC-AD1 Phase 2 Trial

January 05, 2026

Via ACCESS Newswire

IGC Pharma Secures New U.S. Patent as Pharmaceutical Cannabinoids Gain Regulatory Momentum

December 19, 2025

Via ACCESS Newswire

IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines

December 15, 2025

Via ACCESS Newswire

IGC Pharma Announces Coverage Report by Ascendiant Capital Markets about the "Reports Q2 results. We believe more positive clinical data and progress in 2025/26 to be strong catalysts for stock. Raising P/T to $4.75."

December 10, 2025

Via ACCESS Newswire

IGC Pharma Reports 65% Patient Enrollment Milestone in Phase 2 CALMA Alzheimer's Agitation Trial

December 09, 2025

Via ACCESS Newswire

IGC Pharma Announces Publication of Landmark Caregiver Book on Alzheimer's Disease

December 02, 2025

Via ACCESS Newswire

IGC Pharma Leverages MINT-AD to Identify Socioeconomic Risk Factors Driving Alzheimer's and Aging Trends

November 25, 2025

Via ACCESS Newswire

IGC Pharma Reports Accelerated Q2 Progress and Strengthened Financial Focus: CALMA Trial Passes 50% Enrollment Milestone, Strategic Divestiture Optimizes Capital

November 17, 2025

Via ACCESS Newswire

USPTO Grants IGC Pharma Patent Covering IGC-AD1 for Novel Composition Targeting Alzheimer's Disease and Central Nervous System Disorders

November 13, 2025

Via ACCESS Newswire

IGC Pharma to Host Mid-Year Fiscal 2026 Shareholder Update Call on November 17, 2025

November 10, 2025

Via ACCESS Newswire

IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

November 03, 2025

Via ACCESS Newswire

IGC Pharma Advances to Semi-Finals in the Alzheimer's Insights AI Prize with "AHA: Agentic Harmonization Assistant"

October 22, 2025

Via ACCESS Newswire

IGC Pharma Expands Phase 2 CALMA Clinical Trial to University of South Florida's Department of Psychiatry and Behavioral Neurosciences

October 14, 2025

Via ACCESS Newswire

IGC Pharma Announces Results of 2025 Annual Meeting of Stockholders

October 10, 2025

Via ACCESS Newswire

IGC Pharma's Preclinical Data for IGC-1C: New Drug Candidate Potentially Disrupts a Foundational Mechanism of Alzheimer's Disease

October 07, 2025

Via ACCESS Newswire

Frequently Asked Questions

Is IGC Pharma, Inc. Common Stock publicly traded?

Yes, IGC Pharma, Inc. Common Stock is publicly traded.

What exchange does IGC Pharma, Inc. Common Stock trade on?

IGC Pharma, Inc. Common Stock trades on the New York Stock Exchange

What is the ticker symbol for IGC Pharma, Inc. Common Stock?

The ticker symbol for IGC Pharma, Inc. Common Stock is IGC on the New York Stock Exchange

What is the current price of IGC Pharma, Inc. Common Stock?

The current price of IGC Pharma, Inc. Common Stock is 0.2789

When was IGC Pharma, Inc. Common Stock last traded?

The last trade of IGC Pharma, Inc. Common Stock was at 02/24/26 04:10 PM ET

What is the market capitalization of IGC Pharma, Inc. Common Stock?

The market capitalization of IGC Pharma, Inc. Common Stock is 13.88M

How many shares of IGC Pharma, Inc. Common Stock are outstanding?

IGC Pharma, Inc. Common Stock has 14M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.